NCT03816761View on ClinicalTrials.gov

Research Study to Look at Fast-acting Insulin Aspart With the Insulin Pump System 'iLet™' in Adults With Type 1 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 25, 2019

Primary Completion Date

May 31, 2019

Study Completion Date

June 10, 2019

Conditions
Diabetes Mellitus, Type 1
Interventions
DRUG

Fast-acting insulin aspart

In each cohort, participants will receive fast-acting insulin aspart using the iLet™ in a cross-over manner for 14 days (7days per period). Dose modification will be handled autonomously by the iLet™ based on the CGM sensor readings and the user interaction with the iLet™ e.g. meal announcements.

DEVICE

iLet™

The bionic pancreas including pigtail adapters, used in insulin-only configuration

Trial Locations (1)

02114

Novo Nordisk Investigational Site, Boston

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT03816761 - Research Study to Look at Fast-acting Insulin Aspart With the Insulin Pump System 'iLet™' in Adults With Type 1 Diabetes | Biotech Hunter | Biotech Hunter